Varenicline: Quantifying the risk [3]

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 12, 2011, Pages 1404-

  Woods, David J ^a   Caswell, Mark D ^a  

^a Best Practice Advocacy Centre   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOXALINE DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HIGH RISK POPULATION; HUMAN; LETTER; MEDICAL HISTORY; RISK BENEFIT ANALYSIS; SMOKING CESSATION; CHEMICALLY INDUCED DISORDER; NOTE;

BENZAZEPINES; CARDIOVASCULAR DISEASES; HUMANS; NICOTINIC AGONISTS; QUINOXALINES;

EID: 80052517379     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.111-2064     Document Type: Letter

References (1)

1. Singh S., Loke Y.K., Spangler J.G., et al. Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. CMAJ 2011;183:1359-1366